

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
10 May 2001 (10.05.2001)

PCT

(10) International Publication Number  
**WO 01/32101 A1**

- (51) International Patent Classification<sup>7</sup>: A61F 2/02, 2/28 3QQ (GB). FISHER, Timothy, Charles [GB/GB]; 3126 El Caminito Street, La Crescenta, CA 91214 (US).
- (21) International Application Number: PCT/US00/29144
- (22) International Filing Date: 20 October 2000 (20.10.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/162,347 29 October 1999 (29.10.1999) US
- (71) Applicant (for all designated States except US): CHILDREN'S HOSPITAL LOS ANGELES [US/US]; 4650 Sunset Boulevard, Mail Stop 84, Los Angeles, CA 90027 (US).
- (71) Applicant and  
(72) Inventor: LEVY, Michael [US/US]; 14243 Greenleaf Street, Sherman Oaks, CA 91423 (US).
- (72) Inventors; and  
(75) Inventors/Applicants (for US only): WANG, Michael, Y. [US/US]; 432 Oak Knoll #3, Pasadena, CA 91101 (US). ARMSTRONG, Jonathan, Keith [GB/GB]; Cliffview House, Longstreet, Croscombe, Wells, Somerset BAX
- (74) Agent: BERKMAN, Charles, S.; Lyon & Lyon, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071-2066 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— With international search report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



**WO 01/32101 A1**

(54) Title: BONE HEMOSTASIS METHOD AND MATERIALS

(57) Abstract: A method for controlling bleeding from bones, comprising the use of copolymers of oxyethylene and oxypropylene or mixtures thereof to cover the bleeding portions of bones. The copolymers are resorbable by the body, not metabolized, simple to prepare, inexpensive, readily available, and do not interfere with the fusion, osteogenesis, and related tissue healing and repair of the affected bones.

## DESCRIPTION

## BONE HEMOSTASIS METHOD AND MATERIALS

5                        RELATED APPLICATIONS

This application claims priority to the U.S. Provisional Application Serial No. 60/162,347, filed October 29, 1999, by Levy, et al., and entitled "BONE HEMOSTASIS METHOD AND MATERIALS," which is incorporated herein by reference in its entirety, including any drawings.

10                        BACKGROUND OF THE INVENTIONField of the Invention

This invention is in the field of bone hemostasis and involves a method and materials to stop bleeding from bony surfaces via application of copolymers of oxyethylene and oxypropylene during operative procedures or trauma.

Background

During many operative procedures and/or trauma, bones bleed. When such bone bleeding is undesirable and needs to be controlled, cessation of the bleeding, or "hemostasis," has been achieved by several methods in the past. The following methods are presently used to achieve bone hemostasis in surgery requiring fusion of bones:

1.     The bones can be permitted to bleed and external drainage can be made for postoperative hematomas;
2.     Gel foam or cellulose can be applied locally to the bones;
- 25 3.     Direct electrocautery can be applied to bleeding bone surfaces;
4.     Use of a mechanical barrier such as "bonewax" can be applied to the bones.

Bonewaxes used in surgery today are generally prepared from refined beeswax which has been admixed with other nonabsorbable and water insoluble hydrocarbons and vegetable oils. Certain disadvantages are inherent in these bonewax compositions, such

30

as poor adhesion qualities and brittleness of the wax at room temperatures. In addition, paraffin-based commercial bonewax is not absorbed by the body and thus remains at the site of the application for long periods of time. As a result, the wax acts as a foreign material, tending to make it difficult for the body to fight infection and causing  
5 inflammatory reactions that may be introduced into the surrounding tissue. Moreover, the wax interferes with bone regrowth. In addition, bonewax has shown a possible association with increased chromosomal aberrations and teratogenesis in mice. Finally, traditional bonewax has often resulted in the formation of granulomas (a nodular aggregation of inflammatory cells associated with chronic inflammation, which deters  
10 proper healing of separated bones and surrounding tissue).

The following have been reported as substitutes for bonewax: gel foam (gelatin) paste; microcrystalline collagen, fibrin-collagen paste, and bioerodible polyorthoester (Alzamer®).

The desirable characteristics in a bone hemostasis agent are: (1) no detrimental  
15 effects on bony fusion, (2) non-inflammatory; (3) no increased infection rate; (4) non-toxic; (5) inexpensive; (6) non-teratogenic; (7) effective at achieving bone hemostasis quickly; (8) easily resorbed by the body; (9) not metabolized by the body, which prevents possible toxicity from the compound; (10) water soluble; (11) easily prepared; (12) easy to maintain quality control; (13) maintains chemical stability for long periods of time at  
20 room temperature; (14) similar consistency to currently used beeswax. None of the above-listed agents, known agents, or traditional bonewaxes have proven satisfactory in satisfying all these characteristics for a bone hemostasis agent.

The current invention involves the use of copolymers of oxyethylene and oxypropylene. Such copolymers include poloxamers, meroxapols (also known as reverse  
25 poloxamers), poloxamines, and PLURADOT® or PLURACOL® (the proprietary name given by the manufacturer BASF; there is no non-proprietary name for PLURADOT®). The principal supplier of these copolymers is BASF, and BASF has given these copolymers the following proprietary names: poloxamers are known as PLURONIC® surfactants; meroxapols are known as PLURONIC® R surfactants; poloxamines are  
30 known as TETRONIC® surfactants; and PLURACOL® surfactants. As used throughout

this application, the terms “copolymers of oxyethylene and oxypropylene” are inclusive of all four of the above listed BASF copolymers. As used throughout this application, the term “PLURONIC®s” is also inclusive of all four of the above-listed BASF copolymers, except as the context otherwise requires, such as in the case of discussing specific examples of specific poloxamers.

PLURONIC® copolymers are organic polymers of varying chain lengths and oxyethylene and oxypropylene ratios. They were developed in the 1950's by BASF and have a number of medical uses. Such PLURONIC®s are currently available at low cost. For a general discussion of PLURONIC®s, see *Schmolka, I. J., Journal of American Oil and Chemical Society, A Review of Block Polymer Surfactants, 54:110 (1977)* (which is incorporated by reference as if fully set forth herein) A general discussion is also included below in the Examples section.

PLURONIC® copolymers are currently used in variety of medical settings, including suture coating, suppositories, intravenous injection to improve blood rheology, and as an additive in artificial blood substitutes. PLURONIC®s have also been utilized to promote osteogenesis when mixed with demineralized bone powder. Although PLURONIC®s have been used as merely additives in some bone hemostasis agents, no bone hemostasis agent has utilized PLURONIC®s as the base material for the agent, as does this invention.

Bone morphogenetic proteins (BMPs) can promote bone regeneration. *Schmitt, J.M., Hwang, K., Winn, S. R., Hollinger, J. O., “Bone Morphogenetic Proteins: An Update on Basic Biology and Clinical Relevance”, J. Orthop. Res., 1999, 17(2), 269-278* (which is incorporated by reference as if fully set forth herein). However, BMPs applied to a site of bone injury will be rapidly resorbed, and therefore will have minimal efficacy, unless they are administered via an appropriate system to maintain sustained delivery of the protein during the course of bone healing. *Solheim, E., “Growth Factors in Bone”, Int. Orthop., 1998, 22(6), 410-416* (which is incorporated by reference as if fully set forth herein). Incorporation of BMPs with bonewax is a very desirable solution as it (a) enhances the therapeutic value of the bonewax; and (b) eliminates the need for a separate sustained delivery system for the BMPs. However, the required property of any material

intended as a BMP delivery system is that it should be water soluble or water permeable. Current beeswax based bonewaxes are insoluble and impermeable to water and thus would not fulfill this requirement. However, PLURONIC® copolymers are water soluble and hence would serve as an ideal system to sustain BMP delivery.

5

### SUMMARY OF THE INVENTION

The inventions involve a method and materials for controlling bleeding from bones. The method involves applying a PLURONIC® or mixture of PLURONIC®s over the bleeding site of the bone. The materials used are copolymers of oxyethylene and oxypropylene or mixtures of such copolymers. The invention's advantages over conventional agents currently in use is that it will not retard or prevent bone regrowth and fusion, is water soluble and resorbs into the body, is not metabolized but is excreted whole in the urine and is easily prepared from low cost commercially available materials.

10  
15

### BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A-1D represent a comparison of the invention in bone healing with (1) traditional bonewax, and (2) no hemostatic agent being used after a 3mm triangular defect was created in the midshaft of a rat femur.

Fig. 1A is an X-ray of a 3mm triangular defect in the rat femur at day 1 after the defect was created.

Fig. 1B is an X-ray of the femur at 42 days after the defect was created where no hemostatic agent was used on the defect. Fig. 1B represents a control for the experiment.

Fig. 1C represents an X-ray of a rat femur at 42 days after the defect was created where traditional bonewax was used as a hemostatic agent.

Fig. 1D represents an X-ray at 42 days after the defect was made where the copolymer material of this invention was used as a hemostatic agent.

### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

A bone may be broken or cut during surgery or by trauma. Such a cut or broken bone will then bleed. In order to stop bleeding, the method and materials utilized in this

30

invention involve the application of copolymer of oxyethylene and oxypropylene (PLURONIC®) over the site of the bleeding. The PLURONIC® has the general structure of  $\text{HO}-(\text{CH}_2\text{CH}_2\text{O})_A-(\text{CH}(\text{CH}_3)\text{CH}_2\text{O})_B-(\text{CH}_2\text{CH}_2\text{O})_A-\text{H}$ . The PLURONIC® is described generally as a polyoxyethylene-polyoxypropylene-polyoxyethylene triblock copolymer. Thus, there is a hydrophobe (polyoxypropylene) and a hydrophile (polyoxyethylene) present in each PLURONIC® molecule.

In the BASF PLURONIC® code, there are alphabetical and numerical combinations. In BASF's PLURONIC® codes, the alphabetical designation explains the physical form of the product at room temperature: L is for liquids, P is for pastes, and F is for flake (solid) forms. In the numerical designation, the first digit (or the first two digits in a three numeral code) multiplied by 300 indicates the approximate molecular weight of the hydrophobe. The last digit multiplied by 10 indicates the approximate percentage (w/w) of the hydrophile in the PLURONIC®. BASF also makes poloxamers with reverse structures wherein the hydrophilic polyoxyethylene is sandwiched between the hydrophobic polyoxypropylene blocks. This reverse poloxamer or meroxapol is designated as PLURONIC® R by BASF.

Another copolymer which may be used is poloxamine or TETRONIC®, which consists of four chains of polyoxypropylene bounded by four chains of polyoxyethylene. A reverse poloxamine can also be used in which the four chains of ethylene polyoxyethylene are added before the polyoxypropylene. Finally, in PLURADOT® or PLURACOL®, the oxyethylene and oxypropylene are in random order throughout the polymer chain.

As discussed above, PLURONIC® surfactants are currently used in a variety of medical settings. PLURONIC®s range in molecular weight from approximately 1,000 g/mol. to approximately 30,000 g/mol. Low molecular weight PLURONIC®s tend to be liquid in form at room temperature, whereas high molecular weight PLURONIC®s are generally solid at room temperature. Gelling tendencies of PLURONIC®s tend to increase with hydrophile content and with total molecular weight.

In a preferred embodiment of the invention, the PLURONIC® used for the method of stopping bone hemostasis involves a mixture of approximately 10% F88 and 90% P85 where F88 and P85 are PLURONIC® codes utilized by the manufacturer BASF. P85 corresponds to poloxamer code P235 and PLURONIC® code F88  
 5 corresponds to poloxamer code P238. This particular combination of P85 and F88 was utilized because it had the consistency of a wax at room temperature. Other combinations of various copolymers of oxyethylene and oxypropylene or the use of a single copolymer of oxyethylene and oxypropylene may also be appropriate for use as a bone hemostasis agent.

10 The compositions of P85 (P235) and F88 (P238) are as follows:

PLURONIC® Code	Poloxamer Code	Molecular Mass (g/mol)	Polyoxypropylene Content (g/mol)	Polyoxyethylene Content (g/mol)
P85	P235	4650	2250	2400
F88	P238	11400	2250	9150

The approximate percentages for P85 and F88 useful as a bone hemostasis agent range from about 75% - 95% of P85 and about 5% to 25% of F88. The approximate molecular weights of the copolymers useful as bone hemostasis agents range from about  
 15 2000 g/mol to about 30,000 g/mol.

The mixture of PLURONIC® P85 and PLURONIC® F88 set forth in the above-described preferred embodiment was specifically blended in order to mimic the physical properties of beeswax-based bonewaxes. In another preferred embodiment of the present invention, a single PLURONIC® copolymer with similar physical properties to currently  
 20 used beeswax-based bonewaxes would be used. For example, a PLURONIC® with a molecular weight of about 6,000 g/mol, comprising about 60% polyoxyethylene and 40% polyoxypropylene (PLURONIC® code P86), would have comparable physical properties to beeswax-based bonewax.

One method of making the PLURONIC® for bone hemostasis involves placing  
 25 the PLURONIC® or mixture thereof in a single tube and heating it until it is completely liquid. The PLURONIC® is then placed in a sealed pouch and sterilized by autoclave at

121°C for 20 minutes. The sterile pouch is then removed from the autoclave at 80°C and plunged into liquid nitrogen to prevent the formation of crystalline polyoxyethylene.

The PLURONIC® or PLURONIC® mixture is applied to the bleeding portion of a bone via a gloved hand, spatula, syringe or other surgical tool or applicator. A lipstick type applicator which extrudes the copolymer from a cylindrical container by either  
5 pushing a bottom plate or rotating the bottom of the applicator may be used. The PLURONIC® or PLURONIC® mixture has the consistency of beeswax and does not crumble or lose its viscosity to any significant degree at either room or body temperature. Like beeswax, the PLURONIC® can be hand molded to fit a bone defect. Alternatively,  
10 a less viscous PLURONIC® having reverse thermal gelation properties can be applied by syringe to the affected area of the bone and solidifies upon application or shortly thereafter.

The PLURONIC® or PLURONIC® mixture can stop the bleeding from the bones, yet still allow the two separated ends of the bone to fuse back together. The  
15 PLURONIC® or PLURONIC® mixture is water soluble and can be resorbed into the body within approximately 36 hours. In addition, PLURONIC®s are not metabolized but are excreted whole in the urine. In contrast, other hemostasis products often contain chemicals that are metabolized by the body and which may be toxic. PLURONIC®s are non-toxic. The toxicological properties of PLURONIC®s have been investigated since  
20 1952, and they have been shown to have low oral toxicity and low potential for causing irritation or sensitization.

In addition, unlike other bone hemostasis products, PLURONIC®s are very stable at room temperature over long periods of time. Thus, there will be no separation of components or change in form or composition of PLURONIC®s during storage. Also,  
25 because the method described in this invention involves either a single PLURONIC® or mixtures of PLURONIC®s, which are simple to prepare and mix, quality control over the final hemostasis agent is improved over previous compounds which are composed of numerous elements.

The PLURONIC®s of the present invention are well suited to be used to  
30 administer depot preparations of various medications and drugs. These medications may



be mixed with the PLURONIC®s of the present invention and applied to the site of injury. The types of medications that can be used include, but are not limited to: antibiotics, such as aminoglycosides,  $\beta$ -lactam antibiotics, cephalosporins, macrolides, penicillines, tetracyclines, quinolones, and sulfonamides; analgesics, such as acetaminophen, non-steroidal anti-inflammatory agents, salicylates, and narcotics, which may include methadone, morphine, and codeine; chemotherapeutic agents, such as carmustine (BCNU); bone anti-resorption factors, such as risedronate sodium, pamidronate disodium, etidronate disodium, and raloxifene hydrochloride; and bone growth factors, such as calcitonin, TGF Beta (Tumor Growth Factor), and BMP 1 and 2 (bone morphogenic protein).

In addition, the invention relates to a kit for use in trauma situations, which may contain sterile dressings, sterile PLURONIC® or PLURONIC® mixtures, sterile gloves, adhesive tape, a sterile package for the above-described materials and instructions on how to use the kit.


#### EXAMPLES

Experiments showing the usefulness of the method have been performed and are described below:

##### Example 1 - General Characteristics of PLURONIC®

The information in Example 1 was obtained from the BASF web site at [www.BASF.com/business/chemicals/performance/html/PLURONIC\\_grid.html](http://www.BASF.com/business/chemicals/performance/html/PLURONIC_grid.html), as of October 29, 1999.

**The Basic PLURONIC® Grid**



5 This grid represents the relationship between copolymer structure, physical form and surfactant characteristics by plotting molecular weight ranges of the hydrophobe against the percent of hydrophile in the final molecule. The structure of each grade shown on the grid is defined by the intersection of the hydrophobe molecular weight and the percent hydrophile. The PLURONIC® Grid illustrates how gelling tendencies of  
 10 block copolymers increase with hydrophile-content and with total molecular weight.

**Nomenclature and the PLURONIC® Surfactant Grid**

The PLURONIC® Surfactant Grid is a graphic presentation of the PLURONIC® surfactant series. Plotting molecular weight ranges of the hydrophobe (propylene oxide) against the weight-percent of the hydrophile (ethylene oxide) present in each molecule  
 15 allows property trends of the product structure to be analyzed on the Grid. The Grid also

clarifies the use of the letter-number combinations to identify the various products of the PLURONIC® series. The alphabetical designation explains the physical form of the product: 'L' for liquids, 'P' for pastes, 'F' for solid forms. The first digit (two digits in a three-digit number) in the numerical designation, multiplied by 300, indicates the approximate molecular weight of the hydrophobe (vertical axis at the left of the Grid). The last digit, when multiplied by 10, indicates the approximate ethylene oxide content in the molecule, read from the horizontal axis. For example, from the Grid, we immediately learn that PLURONIC® F 68 is a solid material. The molecular weight of the hydrophobe is approximately 1800 (6x300). The hydrophile represents approximately 80% of the molecule, by weight, (8x10).

The PLURONIC® R Surfactant Grid also shows the relationship between the hydrophobe and hydrophile of each product. Again, hydrophobe molecular weight is plotted against weight percent hydrophile. The letter 'R' found in the middle of each designation signifies that this product has a *reverse* structure compared to the PLURONIC® products, i.e., the ethylene oxide (EO) hydrophile is sandwiched between the propylene oxide (PO) blocks. The numeric designation preceding the 'R', when multiplied by 100, indicates the approximate molecular weight of the PO block. The number following the 'R', when multiplied by 10, indicates the approximate weight percent EO in that product.

#### 20 Typical Acute Toxicological Data for Block Copolymers

Block Copolymer Type	Oral LD <sub>50</sub>	Dermal LD <sub>50</sub>	Eye Irritation	Skin Irritation	Skin Sensitization
PLURONIC®	2 to >15g/kg	>5g/kg	Non- to Minimal Irritation	Non- to Slight Irritation	Negative to Mild Sensitization
PLURONIC® R	3 to >10g/kg	>1 to >10g/kg	Minimal to Mild Irritation	Minimal to Slight Irritation	Negative

The PLURONIC® block copolymers have been analyzed in a variety of subchronic and chronic studies. In general, the studies show that the toxicity of these

block copolymers is low and decreases as molecular weight and ethylene oxide content increase. Detailed information for specific products is available on request from BASF.

The effect of PLURONIC® surfactants on aquatic organisms has been evaluated via acute toxicity studies. All the PLURONIC® surfactants tested exhibit low aquatic  
5 toxicity. The LC<sub>50</sub>/EC<sub>50</sub> values for fish, daphnia and algae range from >100 ppm to >2,000 ppm.

The block copolymers are used in a variety of applications and industries that required federal regulatory authorization. In pharmaceutical and medical applications, the FDA has authorized the use of selected block copolymer surfactants.

10

#### Example 2 - Rat Femur Non-Union Model

In a group of Sprague Dawley rats, a 3mm gap was created in femur midshafts by drill, leaving no bony bridge in the gap. The PLURONIC® mixture of 90% P85 and 10% F88 was applied to the bleeding ends of the bone, and the bleeding stopped.

15 Titanium plating was used to maintain the alignment of the femur. The rats were sacrificed at 11 and 22 days and the femurs examined. Histology (using hemotoxylin and eosin stains) showed that the above described PLURONIC® mixture effectively stopped medullary bone bleeding and did not inhibit new bone growth and fusion (osteogenesis).

#### 20 Example 3 - Rat Femur Defect Model

In a group of Sprague Dawley rats, a 3mm triangular wedge was removed from the femur midshafts, leaving a bony bridge as depicted in FIG. 1A. The PLURONIC® mixture of 90% P85 and 10% F88 was applied to the bleeding portion of the bony defect. No plating was utilized to maintain bone alignment or structure. The rats were sacrificed  
25 at 22 and 44 days and the femurs examined. Histology (using hemotoxylin and eosin stains) showed that the above described PLURONIC® mixture was effective in bone hemostasis and that new bone growth occurred without inhibition by the PLURONIC® mixture. X-rays, as shown in FIG. 1D, showed that the PLURONIC® mixture yielded better results than traditional bonewax, as shown in FIG. 1C. X-rays of femurs where the

PLURONIC® mixture was applied, FIG. 1D, showed that regrowth of the bones was not inhibited when compared to a defect where no hemostatic agent was used, FIG. 1B.

Thus, the method and materials of bone hemostasis described in this invention involve the application of a PLURONIC® or PLURONIC® mixture to bleeding bone  
5 surfaces, and the PLURONIC® or PLURONIC® mixture does not inhibit bony fusion and osteogenesis. Since certain changes may be made in the proportions of the ingredients composing the bone hemostasis agent and the bone hemostasis method described in this invention, it is intended that all matter and the process described in the above description shall be interpreted as illustrative and not in a limiting sense.

CLAIMS

What is claimed is:

1. A method of bone hemostasis comprising:
  - 5 (a) observing blood emanating from a bone;
  - (b) locating a cut or break in the bone; and
  - (c) applying a sterile copolymer of oxyethylene and oxypropylene to the cut or break in the bone.
- 10 2. The method of bone hemostasis described in claim 1 wherein the said break or cut to the bone is due to trauma.
3. The method of bone hemostasis described in claim 1 wherein said break or cut to the bone occurs during a surgical procedure.
- 15 4. The method of bone hemostasis described in claim 1 wherein the sterile copolymer comprises a mixture of PLURONIC® polyoxyethylene-polyoxypropylene-polyoxyethylene triblock copolymers.
- 20 5. The method of bone hemostasis described in claim 1 wherein the sterile copolymer comprising a mixture of PLURONIC® copolymers, comprising about 75-95% P85 and about 5-25% F88.
- 25 6. The method of claim 1 further comprising the step of applying the bone hemostasis agent by use of a syringe.
7. A method of bone hemostasis comprising:
  - (a) observing blood emanating from a bone;
  - (b) locating a cut or break in the bone;

- (c) hand molding a sterile copolymer of oxyethylene and oxypropylene to fit the cut or break in the bone;
- (d) applying said sterile copolymer to the cut or break in the bone; and
- (e) confirming that the bleeding has stopped.

5

8. The method of bone hemostasis described in claim 7 wherein the said break or cut to the bone is due to trauma.

9. The method of bone hemostasis described in claim 7 wherein said break or cut to the bone occurs during a surgical procedure.

10

10. The method of bone hemostasis described in claim 7 wherein the sterile copolymer comprises a mixture of PLURONIC® polyoxyethylene-polyoxypropylene-polyoxyethylene triblock copolymers.

15

11. The method of bone hemostasis described in claim 7 wherein the sterile copolymer comprises a mixture of PLURONIC® copolymers, comprising about 75-95% P85 and about 5-25% F88.

20

12. A kit for bone hemostasis comprising:

- (a) a sterile bandage;
- (b) adhesive tape;
- (c) a pair of sterile gloves;
- (d) a sterilized package containing a copolymer of oxyethylene and oxypropylene; and
- (e) a sterile package that contains elements a, b, c and d of this claim.

25

13. A kit for bone hemostasis described in claim 12 containing instructions on how to use the kit.

30

14. A kit for bone hemostasis described in claim 12 containing an antiseptic or other wound sterilizing agent.

15. A kit for bone hemostasis comprising:

- 5 (a) a sterile bandage;
- (b) adhesive tape;
- (c) a pair of sterile gloves;
- (d) a sterilized package of a mixture of copolymers of oxyethylene and oxypropylene; and
- 10 (e) a sterile package that contains elements (a), (b), (c) and (d) of this claim.

16. A kit for bone hemostasis described in claim 15 containing instructions on how to use the kit.

15

17. A kit for bone hemostasis described in claim 15 wherein the mixture of copolymers of oxyethylene and oxypropylene is further comprised of about 75-95% P85 and about 10-25% F88.

20

18. A kit for bone hemostasis described in claim 15 containing an antiseptic or other wound sterilizing agent.

19. A non-toxic, resorbable bone hemostasis agent consisting essentially of a copolymer of oxyethylene and oxypropylene.

25

20. A non-toxic, resorbable bone hemostasis agent consisting essentially of a mixture of copolymers of oxyethylene and oxypropylene.

21. The non-toxic, resorbable bone hemostasis agent of claim 20, comprising:

- 30 (a) about 75 to 95 percent P85; and



(b) about 5 to 25 percent F88.

22. The non-toxic, resorbable bone hemostasis agent of claim 20 comprising:

(c) about 90% P85; and

5 (d) about 10% F88.

23. A non-toxic, hand-moldable, resorbable bone hemostasis agent consisting essentially of a copolymer of oxyethylene and oxypropylene.

10 24. A non-toxic, hand-moldable, resorbable bone hemostasis agent consisting essentially of a mixture of copolymers of oxyethylene and oxypropylene.

25. The non-toxic, hand-moldable, resorbable bone hemostasis agent of claim 24, comprising:

15 (a) about 75 to 95 percent P85; and

(b) about 5 to 25 percent F88.

26. The non-toxic, hand-moldable, resorbable bone hemostasis agent of claim 24 comprising:

20 (a) about 90% P85; and

(b) about 10% F88.

27. The non-toxic, resorbable bone hemostasis agent of claim 19 further comprising an agent to enhance wound healing and accelerate osteogenesis.

25

28. The non-toxic, resorbable bone hemostasis agent of claim 20 further comprising an agent to enhance wound healing and accelerate osteogenesis.

29. The non-toxic, resorbable bone hemostasis agent of claim 28 wherein said agent to enhance wound healing and accelerate osteogenesis is bone morphogenic protein.

5 30. The non-toxic, resorbable bone hemostasis agent of any one of claims 20-26, further comprising a medication.

10 31. The non-toxic, resorbable bone hemostasis agent of claims 30, wherein said medication is selected from the group consisting of antibiotics, analgesics, chemotherapeutic agents, bone anti-resorption factors, and bone growth factors, or a combination thereof.

15 32. The non-toxic, resorbable bone hemostasis agent of claims 31, wherein said antibiotic is selected from the group consisting of aminoglycosides,  $\beta$ -lactam antibiotics, cephalosporins, macrolides, penicillines, tetracyclines, quinolones, and sulfonamides.

20 33. The non-toxic, resorbable bone hemostasis agent of claims 31, wherein said acetaminophen, non-steroidal anti-inflammatory agents, salicylates, and narcotics.

34. The non-toxic, resorbable bone hemostasis agent of claims 31, wherein said chemotherapeutic agent is carmustine.

25 35. The non-toxic, resorbable bone hemostasis agent of claims 31, wherein said bone anti-resorption factor is selected from the group consisting of risedronate sodium, pamidronate disodium, etidronate disodium, and raloxifene hydrochloride.

30 36. The non-toxic, resorbable bone hemostasis agent of claims 31, wherein said bone growth factors is selected from the group consisting of calcitonin, Tumor Growth Factor Beta, Bone Morphogenic Protein 1, and Bone Morphogenic Protein 2.

# INTERNATIONAL SEARCH REPORT

Int. national application No.  
PCT/US00/29144

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) : A61F 2/02, 2/28  
US CL. : 424/426; 523/115; 623/16

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/426; 523/115; 623/16

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5,520,923 A (TJIA ET AL) 28 MAY 1996, see entire document.	1-36

Further documents are listed in the continuation of Box C.       See patent family annex.

<p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claims or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, lecture, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"F" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"A'" document or member of the same patent family</p>
--	---

Date of the actual completion of the international search <b>04 DECEMBER 2000</b>	Date of mailing of the international search report <b>29 DEC 2000</b>
--	--

Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer <i>Dorothea Lawrence For</i> CARLOS AZPURU Telephone No. (703) 308-1235
---	---